Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer. Telli, M. L., Kurian, A. W., Jensen, K. C., Vinayak, S., Flaherty, P., Lipson, J. A., Wapnir, I., Daniel, B., Carlson, R. W., Mills, M. A., Chang, P., Schackmann, E., Rocha, C., Sherman, B., Blackwood-Chirchir, A., Bradley, C., Ford, J. M. AMER ASSOC CANCER RESEARCH. 2011
View details for DOI 10.1158/0008-5472.SABCS11-P3-14-08
View details for Web of Science ID 000209699801149